immun
pig
modifi
live
porcin
reproduct
respiratori
syndrom
viru
prrsv
vaccin
initi
elicit
weak
interferon
ifn
g
respons
improv
immun
respons
adjuv
consist
plasmid
encod
either
porcin
interleukin
il
ifna
coadminist
vaccin
presenc
either
adjuv
least
threefold
increas
primari
virusspecif
ifng
respons
observ
enhanc
transient
week
express
plasmid
use
effect
still
appar
week
vaccin
presenc
ifna
express
plasmid
even
challeng
virul
genet
diverg
prrsv
contrast
effect
either
adjuv
product
antiviru
antibodi
notic
throughout
studi
despit
appar
augment
helper
th
type
respons
inclus
ifna
vaccin
modul
necessarili
correl
reduct
viremia
sinc
similar
increas
degre
ifng
respons
prrsv
vaccin
could
achiev
substitut
polyinosinicpolycytidyl
acid
lieu
either
cytokin
exposur
prrsv
presenc
varieti
th
polar
molecul
posit
influenc
develop
cellmedi
immun
respons
swine
pathogen
conceiv
intervent
could
appli
improv
formul
antiprrsv
vaccin
porcin
reproduct
respiratori
syndrom
prr
econom
import
diseas
swine
character
abort
stillbirth
weakborn
pig
nonreproduct
form
syndrom
affect
younger
pig
sever
older
anim
caus
reduc
growth
pneumonia
made
sever
coinfect
pathogen
thacker
etiolog
agent
diseas
rna
viru
prrsv
belong
famili
arterivirida
target
macrophag
infect
wensvoort
et
al
collin
et
al
prrsv
exhibit
signific
degre
genet
diversif
murtaugh
et
al
key
et
al
goldberg
et
al
characterist
probabl
contribut
difficulti
control
infecti
outbreak
caus
meng
experiment
condit
current
avail
modifi
live
viru
mlv
vaccin
pathogen
shown
provid
immun
pig
adequ
protect
subsequ
challeng
homolog
strain
lager
et
al
lager
et
al
howev
despit
demonstr
abil
vaccin
afford
pig
partial
protect
infect
genet
diverg
prrsv
strain
osorio
et
al
lager
et
al
mengel
et
al
mengel
et
al
overal
protect
immun
provid
swine
commerci
set
gener
inadequ
halbur
infect
pig
wild
type
prrsv
nelson
et
al
loemba
et
al
vezina
et
al
yoon
et
al
albina
et
al
gonin
et
al
vaccin
live
attenu
form
viru
labarqu
et
al
ostrowski
et
al
elicit
exuber
product
nonneutr
antibodi
contrast
transient
cell
mediat
prrsvspecif
lymphoprolif
respons
detect
week
postinfect
last
addit
bautista
molitor
week
lopezfuert
et
al
moreov
time
interv
limit
quantiti
ifng
secret
cell
sc
also
gener
meier
et
al
xiao
et
al
interestingli
absenc
addit
antigen
stimul
polar
revers
within
ensu
month
manifest
decreas
antibodi
respons
gradual
increas
intens
ifng
respons
meier
et
al
initi
antibodydomin
immun
respons
result
insuffici
antigen
stimul
sinc
neither
inclus
commerci
adjuv
primari
vaccin
meier
et
al
booster
immun
previous
heavili
vaccin
pig
bassaganyariera
et
al
enhanc
virusspecif
cellmedi
immun
cmi
thu
prrsv
seem
inher
stimul
imbalanc
immun
respons
character
abund
humor
immun
limit
potenti
protect
th
ifng
respons
one
characterist
prrsv
infect
probabl
contribut
retard
develop
specif
cellmedi
immun
respons
lack
induc
ifna
product
albina
et
al
buddaert
et
al
van
reeth
et
al
usual
virusinfect
cell
secret
type
ifn
releas
cytokin
interact
subset
cell
promot
convers
virusspecif
ifng
sc
cella
et
al
cousen
et
al
kadowaki
et
al
biron
levi
et
al
howev
counteract
viru
poor
induc
type
ifn
develop
th
respons
gener
pathway
util
interleukin
il
cousen
et
al
biron
inde
inject
recombin
time
vaccin
three
addit
time
follow
week
enhanc
host
cellular
immun
respons
prrsv
foss
et
al
base
success
intervent
note
absenc
ifna
gener
prrsv
infect
present
studi
undertaken
determin
antivir
adapt
immun
induc
vaccin
prr
mlv
could
modifi
simpli
coadministr
protein
directli
either
porcin
ifna
indirectli
via
plasmid
express
cytokin
addit
two
element
deliv
th
polar
signal
biron
kadowaki
liu
kapsenberg
effect
stimul
known
induc
ifna
product
name
doublestrand
rna
examin
although
three
adjuv
posit
influenc
intens
rate
develop
virusspecif
ifng
respons
result
indic
stronger
immunomodul
need
overcom
tendenc
prrsv
elicit
type
th
respons
prior
use
immun
ingelvac
prr
mlv
vaccin
boehring
ingelheim
vetmedica
inc
st
joseph
mo
reconstitut
lyophil
vial
accord
manufactur
instruct
highli
virul
atyp
prrsv
strain
genbank
access
number
origin
isol
sever
case
reproduct
failur
iowa
swine
herd
use
challeng
viru
anim
studi
extent
nucleotid
sequenc
ident
wildtyp
strain
parent
strain
vaccin
use
studi
approxim
elispot
assay
prrsvspecif
ifng
sc
prrsv
strain
american
type
cultur
collect
manassa
va
use
sourc
antigen
requir
prrsv
propag
titrat
monolay
cell
previous
describ
meier
et
al
porcin
peripher
blood
mononuclear
cell
pbmc
isol
venou
blood
anticoagul
mm
heparin
cell
subsequ
maintain
describ
meier
et
al
gener
plasmid
capabl
express
ifna
mammalian
host
intact
cdna
encod
porcin
ifna
first
prepar
rtpcr
use
rna
isol
pig
lymphocyt
previous
infect
pseudorabi
viru
stimul
ifna
product
forward
tctgcaaggttcccaatg
revers
gtctgtcactccttcttcctg
primer
design
base
nucleotid
sequenc
porcin
ifna
cdna
lefevr
la
bonnardier
product
anticip
size
bp
clone
pcr
plasmid
invitrogen
corp
carlsbad
ca
insert
predict
restrict
enzym
site
sequenc
comparison
code
region
within
select
amplicon
previous
report
ifna
cdna
reveal
three
nucleotid
differ
variat
result
two
amino
acid
chang
tyrosin
cystein
posit
arginin
leucin
posit
intact
protein
ifna
cdna
excis
recombin
pcr
plasmid
place
transcript
regul
cytomegaloviru
promot
invitrogen
gener
pina
verifi
activ
cytokin
encod
amplifi
cdna
chines
hamster
ovari
cho
cell
transfect
pina
singl
cell
clone
resist
mg
geneticin
per
ml
growth
medium
prepar
supernat
medium
clone
test
abil
inhibit
replic
interferoninduc
neg
strain
vesicular
stomat
viru
sekellick
marcu
madin
derbi
bovin
kidney
mdbk
cell
previous
describ
rubinstein
et
al
clone
produc
greater
unit
unit
inhibit
vsv
replic
mdbk
cell
monolay
ifna
detect
gener
plasmid
capabl
express
composit
moieti
consist
subunit
join
tandem
inert
amino
acid
stretch
mammalian
cell
cdna
encod
amino
acid
long
leader
region
amino
acid
matur
form
subunit
first
deriv
plasmid
race
provid
dr
mp
murtaugh
univers
minnesota
contain
approxim
half
subunit
cdna
fragment
insert
ligat
segment
excis
yeast
express
plasmid
foss
et
al
consist
remaind
subunit
cdna
link
nucleotid
stretch
cdna
encod
matur
form
subunit
result
plasmid
util
cytomegaloviru
promot
regul
express
complet
complex
consist
one
two
subunit
verifi
biolog
activ
secret
cytokin
could
produc
cho
cell
either
mocktransfect
transfect
plasmid
h
overlay
medium
subject
bioassay
design
demonstr
presenc
porcin
base
abil
increas
ifng
respons
memori
cell
recal
viral
antigen
meier
et
al
comparison
yeastderiv
porcin
standard
provid
dr
moodi
endogen
woburn
ngml
bioactiv
cytokin
found
transfect
cell
medium
wherea
activ
found
associ
control
supernat
escherichia
coli
strain
invitrogen
transfect
either
pina
grown
l
lb
medium
supplement
mgml
ampicillin
sigma
st
loui
mo
h
constant
shake
rpm
plasmid
purif
conduct
use
qiagen
plasmid
maxi
kit
qiagen
inc
valencia
ca
accord
manufactur
instruct
plasmid
pina
precipit
onto
surfac
gold
particl
averag
diamet
mm
biorad
laboratori
inc
hercul
ca
concentr
mg
dnamg
gold
plastic
tube
coat
mg
dnabound
gold
particl
use
tube
prep
station
biorad
follow
manufactur
instruct
cut
yield
cartridg
contain
mg
dna
immedi
prior
use
standard
bioassay
adjuv
anim
studi
lyophil
yeastderiv
porcin
endogen
reconstitut
low
endotoxintest
pb
mediatech
herndon
va
concentr
mgml
stabil
polyinosin
polycytidyl
acid
poli
c
prepar
method
levi
et
al
minor
modif
briefli
poli
c
sigma
mgml
pyrogenfre
nacl
denatur
h
allow
reanneal
cool
slowli
ambient
temperatur
anneal
poli
c
solut
mix
equal
volum
mg
polyllysineml
pyrogenfre
nacl
carboxymethylcellulos
pyrogenfre
nacl
final
prepar
store
need
first
studi
yorkshir
x
landrac
crossbr
pig
obtain
prrsvfree
herd
randomli
segreg
five
group
n
sixth
group
two
individu
latter
group
kept
prrsvfree
environ
vaccin
challeng
anim
immun
adductor
muscl
inner
thigh
ml
ingelvac
prr
mlv
vaccin
time
pig
inocul
intramuscularli
im
needl
either
ml
salin
group
mg
pina
group
group
per
anim
intraderm
id
mg
group
via
biolist
deliveri
gene
gun
biorad
locat
adjac
site
vaccin
twenti
microgram
porcin
ml
volum
coadminist
member
group
also
receiv
second
im
inject
cytokin
h
later
week
postimmun
pig
receiv
vaccin
except
one
group
vaccin
conjunct
im
applic
either
plasmid
pina
group
group
transfer
biocontain
facil
togeth
five
addit
pig
group
obtain
herd
mention
time
transfer
anim
challeng
tcid
ml
mlnostril
prrsv
strain
fourteen
day
later
pig
euthan
second
studi
twelv
yorkshir
landrac
crossbr
pig
obtain
prrsvfree
herd
describ
randomli
assign
one
two
group
n
pig
immun
im
ml
ingelvac
prr
mlv
vaccin
mg
poli
ckg
bodi
weight
coadminist
anim
one
group
dose
poli
c
select
base
demonstr
abil
induc
maximum
presenc
ifna
sera
pig
loewen
derbyshir
pig
bled
h
poli
c
administr
differenti
white
blood
cell
number
determin
celldyn
abbott
laboratori
abbott
park
il
confirm
microscopi
experienc
technician
eight
week
later
member
group
given
secondari
booster
immun
ident
composit
primari
vaccin
extent
host
cellmedi
immun
respons
prrsv
measur
use
singl
cell
elispot
assay
meier
et
al
enumer
virusspecif
ifngsc
pbmc
popul
presenc
prr
virusneutr
vn
antibodi
sera
determin
previous
describ
benfield
et
al
briefli
twofold
serial
dilut
serum
ml
modifi
eagl
minim
essenti
medium
mem
mix
equal
volum
mem
contain
tcid
select
prrsv
strain
incub
h
mixtur
ad
monolay
cell
tissu
cultur
plate
cell
examin
daili
interv
end
point
titer
express
reciproc
highest
serum
dilut
neutral
develop
prrsvinduc
cytopath
effect
quantiti
nonneutr
prrsvspecif
antibodi
sera
measur
use
commerci
elisa
assay
herdchek
prr
idexx
westbrook
sampl
posit
sp
ratio
greater
consid
posit
calcul
base
manufactur
instruct
util
formula
sp
test
sampl
prrsv
antigen
test
sampl
normal
host
cell
antigen
posit
control
prrsv
antigen
posit
control
normal
host
cell
antigen
viru
detect
serum
sampl
collect
day
postprrsv
challeng
tonsil
biopsi
obtain
termin
experi
prior
use
tonsil
g
first
homogen
grind
tissu
pestl
ml
microfug
tube
ad
ml
mem
supplement
mg
gentamicin
per
ml
vigor
shake
sampl
pestl
tube
remov
pestl
addit
ml
mem
ad
homogen
mix
vigor
suspens
pass
mm
pores
filter
store
detect
infecti
prrsv
quadrupl
set
cell
monolay
plate
incub
either
ml
serial
dilut
serum
tonsil
homogen
start
dilut
mem
supplement
mg
gentamicin
per
ml
h
co
afterward
inocula
remov
replac
ml
mem
supplement
fetal
calf
serum
mg
gentamicin
per
ml
cell
incub
day
check
daili
sign
cytopath
effect
result
express
mean
ae
standard
error
mean
se
statist
signific
determin
analysi
varianc
signific
differ
confid
level
present
individu
differ
treatment
group
determin
fisher
protect
least
signific
differ
plsd
comparison
quantiti
viru
sera
tonsil
done
use
fisher
exact
test
analys
perform
statview
program
abacu
concept
berkeley
ca
immun
pig
prr
mlv
vaccin
induc
rel
mild
cmi
respons
ensu
week
evidenc
low
frequenc
prrsvspecif
ifng
sc
vaccin
pig
pbmc
popul
fig
although
similar
respons
evid
time
period
vaccin
pig
also
im
inject
exogen
either
directli
protein
indirectli
via
cdna
immun
anim
id
inocul
cdna
exhibit
overal
transient
increas
frequenc
prrsvspecif
ifng
sc
week
postvaccin
likewis
slightli
greater
enhanc
threefold
found
vaccin
anim
receiv
ifna
cdna
howev
case
ifng
respons
remain
elev
extent
throughout
follow
week
sinc
pig
immun
prrsv
mlv
presenc
pina
exhibit
significantli
enhanc
sustain
ifng
respons
compar
vaccin
group
anim
well
receiv
vaccin
vaccin
plu
im
inject
transfer
biocontain
facil
challeng
prrsv
strain
control
addit
group
age
match
pig
includ
also
infect
virul
viru
week
challeng
anim
origin
immun
presenc
ifna
cdna
continu
display
statist
signific
greater
ifng
respons
rel
measur
pig
mlvvaccin
pig
exhibit
strongli
posit
antiprrsv
antibodi
titer
sp
ratio
rang
week
follow
immun
level
humor
immun
increas
measur
week
later
sp
ratio
rang
fig
howev
signific
differ
mean
sp
ratio
cohort
receiv
vaccin
alon
group
whose
vaccin
supplement
cytokin
adjuv
contrast
vn
antibodi
detect
week
immun
low
titer
v
v
one
two
pig
per
group
tabl
differ
variou
cohort
regard
proport
pig
contain
vn
antibodi
found
signific
immedi
prior
challeng
virul
prrsv
strain
week
postvaccin
vn
antibodi
detect
serum
collect
member
three
cohort
challeng
mlv
mlv
im
mlv
pina
im
fig
although
subsequ
week
postchalleng
major
pig
develop
detect
vn
antibodi
respons
three
group
could
still
statist
differenti
base
averag
vn
titer
despit
use
challeng
strain
lieu
prrsv
isol
antigen
sourc
appear
result
slightli
sensit
assay
presenc
vn
antibodi
visual
differ
determin
statist
signific
expect
due
short
interv
exposur
viru
perform
assay
prrsvneutral
antibodi
inject
porcin
daili
interv
group
addit
group
serv
unvaccin
control
group
week
postimmun
vaccin
anim
group
well
five
newli
acquir
pig
challeng
control
group
challeng
prrsv
strain
pbmc
isol
pig
indic
time
postvaccin
presenc
virusspecif
ifng
sc
determin
use
elispot
assay
asterisk
indic
signific
differ
p
frequenc
ifng
sc
blood
anim
immun
mlvalon
compar
immun
group
valu
repres
mean
respons
five
anim
ae
sem
except
group
downsiz
four
pig
immedi
prior
challeng
group
consist
two
anim
unvaccin
nd
serum
drawn
member
group
describ
legend
fig
indic
time
vaccin
assay
presenc
viru
neutral
vn
antibodi
prrsv
isol
b
numer
valu
repres
number
vn
posit
pig
denomin
valu
repres
total
number
pig
respect
group
vn
titer
posit
sampl
either
viru
isol
c
done
fig
comparison
presenc
prrsvneutral
antibodi
serum
vaccin
pig
challeng
wild
type
prrsv
immedi
prior
week
challeng
prrsv
strain
serum
drawn
four
member
group
pig
group
describ
legend
fig
assay
presenc
prrsvneutral
antibodi
result
present
reciproc
lowest
twofold
dilut
serum
inhibit
replic
either
prrsv
strain
cell
monolay
valu
repres
mean
prrsv
neutral
antibodi
titer
blood
five
anim
ae
sem
except
group
downsiz
four
pig
immedi
prior
challeng
detect
sera
challeng
nonvaccin
pig
day
postprrsv
challeng
one
four
pig
immun
mlv
vaccin
alon
group
three
five
pig
immun
conjunct
im
inject
group
detect
viremia
level
sensit
tcid
ml
serum
fig
contrast
time
unvaccin
pig
group
receiv
pina
combin
vaccin
virem
group
three
day
later
three
five
anim
inject
pina
group
well
nonimmun
pig
group
remain
virem
level
sensit
tcid
ml
serum
day
postchalleng
viru
could
found
serum
one
unvaccin
pig
none
vaccin
pig
level
sensit
tcid
ml
serum
prrsv
also
detect
tonsil
three
five
nonimmun
anim
biopsi
remov
vaccin
pig
experi
termin
day
challeng
level
sensit
tcid
g
tissu
lower
sensit
viru
detect
assay
day
challeng
due
toxic
serum
dilut
toxic
effect
present
serum
sampl
collect
day
challeng
evalu
impact
poli
c
host
respons
prrsv
immun
statu
pig
receiv
mlv
vaccin
alon
conjunct
synthet
doublestrand
rna
revaccin
formul
week
later
monitor
total
week
nearli
immedi
effect
poli
c
pig
observ
evidenc
approxim
reduct
quantiti
white
blood
cell
peripher
blood
compar
anim
h
fig
comparison
viru
titer
sera
tonsil
vaccin
pig
challeng
wild
type
prrsv
serum
drawn
four
member
group
pig
group
describ
legend
fig
day
postchalleng
prrsv
strain
tonsil
biopsi
obtain
day
challeng
viruschalleng
pig
viru
titer
log
tcid
per
ml
serum
per
gram
tonsil
present
pig
circl
limit
detect
assay
indic
dot
line
valu
level
place
line
bar
indic
mean
four
five
measur
titer
within
group
statist
signific
p
p
base
differ
percent
virem
pig
indic
treatment
group
determin
fisher
exact
test
administr
compound
leukopenia
transient
longer
appar
h
later
data
shown
week
postimmun
poli
ctreat
pig
also
exhibit
signific
increas
frequenc
prrsvspecif
ifng
sc
compar
untreat
pig
fig
enhanc
taper
still
measur
week
later
time
second
immun
signific
differ
frequenc
ifng
sc
two
group
detect
howev
week
booster
immun
frequenc
virusspecif
ifng
sc
poli
ctreat
anim
increas
comparison
untreat
animalsin
case
statist
signific
ensu
interv
termin
experi
differ
two
group
regard
paramet
observ
although
prrsvspecif
antibodi
readili
detect
pig
sera
collect
week
postprimari
immun
signific
differ
found
exist
averag
antibodi
titer
poli
ctreat
untreat
group
data
shown
data
present
demonstr
adjuv
effect
ifna
provid
exogen
form
express
cdna
pina
circuit
via
induct
ifna
synthesi
poli
c
vaccineinduc
ifng
respons
prrsv
howev
despit
posit
modul
th
immun
signific
alter
develop
humor
immun
respons
observ
thu
even
intervent
initi
prrsv
immun
usual
rapid
onset
antiprrsv
antibodi
product
delay
appear
vn
antibodi
labarqu
et
al
ostrowski
et
al
meier
et
al
still
occur
although
previou
studi
similar
increas
presenc
prrsvspecif
ifng
sc
afford
pig
receiv
multipl
inject
time
vaccin
ensu
week
foss
et
al
use
convent
oilinwat
adjuv
found
ineffect
regard
meier
et
al
moreov
studi
even
though
compound
demonstr
enhanc
genesi
vn
antibodi
recogn
pseudorabi
viru
addit
specif
ifng
sc
intens
either
type
immun
respons
prrsv
affect
appar
prrsv
possess
inher
structur
element
prevent
time
develop
protect
innat
adapt
immun
capabl
inhibit
infecti
process
thu
ultim
outcom
interact
viru
host
determin
elicit
host
respons
highli
variabl
evidenc
inconsist
clinic
outcom
seen
upon
challeng
immun
pig
prrsv
labarqu
et
al
mengel
et
al
mengel
et
al
like
due
signific
variabl
within
swine
popul
regard
innat
adapt
immun
respons
prrsv
xiao
et
al
royae
et
al
fig
comparison
intens
virusspecif
ifng
sc
respons
pig
immun
prr
mlv
vaccin
absencepres
poli
c
group
pig
vaccin
prr
mlv
alon
conjunct
poli
c
interv
pbmc
isol
pig
indic
time
postvaccin
presenc
virusspecif
ifng
sc
determin
use
elispot
assay
signific
differ
p
frequenc
ifng
sc
blood
two
group
indic
asterisk
valu
repres
mean
respons
six
anim
ae
sem
abil
prrsv
initi
elicit
protect
immun
infect
host
rel
novel
among
virus
even
inactiv
usual
still
promot
th
respons
de
wit
et
al
regard
notabl
ifna
respons
exposur
prrsv
nearli
nonexist
exampl
ifna
product
lung
pig
acut
infect
prrsv
either
almost
undetect
lower
induc
anoth
pathogen
porcin
respiratori
coronaviru
prcv
buddaert
et
al
van
reeth
et
al
lack
effici
stimul
ifna
product
pathogen
signific
impact
natur
host
adapt
immun
respons
sinc
ifna
upregul
ifng
gene
express
thu
control
domin
pathway
promot
develop
adapt
immun
name
cellmedi
ifng
respons
peak
antivir
immun
defens
cousen
et
al
levi
et
al
regard
becom
evid
link
innat
adapt
immun
viral
infect
occur
interact
dendrit
cell
type
interferon
montoya
et
al
tough
dendriticcel
control
polar
tcell
function
kapsenberg
product
ifna
plasmacytoid
dendrit
cellsnatur
ifnabproduc
cell
nipc
autocrin
effect
promot
function
phenotyp
activ
necessari
optim
express
costimulatori
molecul
subsequ
abil
caus
cell
differenti
ifngsc
cella
et
al
kadowaki
et
al
fitzgeraldbocarsli
montoya
et
al
honda
et
al
presum
prrsv
poor
induc
ifna
product
nipc
sinc
unlik
transmiss
gastroenter
viru
charley
laven
nowacki
et
al
typea
cpg
oligonucleotid
guzylackpiri
et
al
fail
stimul
secret
ifna
cultur
porcin
pbmc
albina
et
al
zuckermann
et
al
unpublish
observ
thu
direct
examin
outcom
interact
prrsv
porcin
nipc
like
reveal
import
inform
immunobiolog
viru
especi
sinc
viru
suscept
antivir
effect
ifna
albina
et
al
applic
molecular
tool
realtim
pcr
assay
measur
express
key
immun
mediat
regul
develop
th
respons
swine
particularli
use
endeavor
note
absenc
ifnab
product
cytokin
whose
synthesi
induc
viral
infect
orang
biron
increas
ifng
product
cell
cousen
et
al
thu
two
altern
rout
type
ifndepend
lead
adapt
th
cellmedi
immun
respons
potent
antivir
effect
biron
accord
scenario
involv
presenc
less
requisit
amount
ifna
could
provid
necessari
impetu
develop
antivir
ifng
respons
regard
mrna
detect
porcin
macrophag
infect
prrsv
thanawongnuwech
et
al
transient
lung
prrsvinfect
pig
chung
chae
howev
pathogen
also
appar
poor
stimul
product
sinc
neglig
quantiti
mrna
protein
produc
porcin
pbmc
expos
vitro
prrsv
zuckermann
et
al
unpublish
observ
observ
inclus
either
ifna
immun
increas
intens
ifng
respons
prrsv
valid
propos
role
two
innat
cytokin
direct
vivo
differenti
swine
th
cell
help
explain
poor
virusspecif
ifng
respons
normal
develop
result
exposur
pig
prrsv
meier
et
al
xiao
et
al
compens
lack
stimul
innat
cytokin
express
prrsv
novel
adjuv
use
immun
administr
combin
live
kill
prrsv
vaccin
result
increas
lymphoprolif
respons
viru
wee
et
al
inclus
either
combin
cholera
toxin
correl
enhanc
respons
prrsv
week
initi
exposur
foss
et
al
moreov
studi
frequenc
virusspecif
ifng
sc
transient
increas
week
postvaccin
pig
also
inject
porcin
although
similar
result
obtain
current
studi
albeit
biolist
inject
express
cdna
lieu
protein
provis
ifna
cdna
pronounc
sustain
effect
intens
cellmedi
immun
respons
notabl
id
administr
cdna
gene
gun
success
enhanc
vaccineinduc
ifng
respons
im
inject
plasmid
observ
agreement
report
higher
effici
vivo
dna
transfect
biolist
deliveri
fynan
et
al
colosimo
et
al
greater
effect
plasmid
encod
ifna
rather
entic
ifng
respons
could
attribut
rel
low
amount
complet
receptor
swine
lymphocyt
limit
upregul
express
receptor
subunit
gene
compar
speci
solanoaguilar
et
al
regard
note
inject
bioactiv
pig
stimul
strong
cell
respons
solanoaguilar
et
al
likewis
introduct
known
induc
ifna
product
pig
poli
c
derbyshir
lesnick
vaccin
temporarili
amplifi
quantiti
prrsvspecif
ifng
sc
effici
ifna
encod
plasmid
enhanc
ifng
respons
vaccin
differ
could
attribut
presenc
immunostimulatori
cpg
motif
eukaryot
express
vector
use
studi
express
cytokin
gene
shown
induc
ifng
express
porcin
leukocyt
magnusson
et
al
plausibl
combin
direct
stimul
nipc
cpg
motif
ifnaencod
plasmid
presum
tolllik
receptor
shimosato
et
al
combin
plasmiddriven
product
ifna
would
provid
necessari
stimulatori
signal
promot
matur
dendrit
cell
creation
microenviron
conduc
sustain
ifng
respons
prrsv
although
poli
c
induc
ifna
product
entic
porcin
nipc
differenti
guzylackpiri
et
al
thu
might
provid
enough
impetu
promot
sustain
tcellmedi
ifng
respons
viru
notion
agreement
role
attribut
cpgcontain
oligonucleotid
promot
matur
nipc
human
krug
et
al
swine
guzylackpiri
et
al
inabl
ifna
cdna
enhanc
vn
antibodi
respons
prrsv
contrast
posit
effect
exert
coadministr
adenoviru
express
ifna
combin
footandmouth
diseas
viru
fmdv
subunit
vaccin
pig
notion
structur
inher
properti
uniqu
prrsv
deter
elicit
strong
vn
antibodi
respons
accord
observ
case
prrsvneutral
antibodi
close
associ
nearbi
nglycan
recogn
epitop
viru
envelop
glycoprotein
may
imped
neutral
viru
plagemann
et
al
addit
decoy
epitop
delay
develop
vn
antibodi
also
exist
ostrowski
et
al
remark
shown
titer
vn
antibodi
increas
equal
vaccin
group
result
pig
challeng
genet
diverg
virul
viru
similarli
augment
titer
vn
antibodi
prrsv
observ
pig
previous
vaccin
prr
mlv
receiv
booster
immun
inactiv
genet
diverg
viru
expos
attenu
viru
osorio
et
al
bassaganyariera
et
al
compar
control
prrsv
pig
lower
proport
vaccin
prr
mlv
exhibit
viremia
day
challeng
howev
reduct
observ
anim
also
receiv
either
ifna
rather
inject
pina
increas
percentag
virem
pig
although
mean
viru
titer
sera
intermedi
valu
determin
vaccin
unvaccin
group
day
challeng
signific
observ
regard
protect
immun
unclear
due
fact
vaccin
decreas
durat
magnitud
viremia
follow
experiment
challeng
van
woensel
et
al
verheij
et
al
reduct
viremia
necessarili
associ
commensur
amelior
sever
clinic
paramet
associ
prr
lessen
rate
weight
gain
fever
respiratori
distress
viru
transmiss
sentinel
pig
nodelijk
et
al
labarqu
et
al
mengel
et
al
similar
lack
correl
viremia
clinic
sign
also
note
two
differ
age
group
nonimmun
pig
infect
prrsv
wherea
greater
frequenc
viremia
accompani
higher
viru
titer
found
younger
anim
month
age
older
pig
month
age
exhibit
sever
clinic
sign
difficulti
deciph
prrsv
biolog
reveal
mark
degre
variabl
irreproduc
consecut
trial
conduct
investig
labarqu
et
al
mengel
et
al
mengel
et
al
moreov
although
posit
associ
protect
diseas
intens
ifng
respons
swine
observ
regard
pseudorabi
viru
van
rooij
et
al
similar
relationship
concern
prrsv
appar
result
studi
thu
identif
immunolog
mechan
respons
mediat
protect
immun
prrsv
pose
signific
challeng
perhap
requir
monitor
extent
reproduct
failur
caus
viru
measur
degre
protect
lager
et
al
notabl
recent
relat
field
studi
notic
posit
correl
reduct
abortionstil
birth
sow
rel
frequenc
prrsvspecif
ifng
sc
blood
low
et
al
event
perhap
mark
enhanc
vaccineinduc
ifng
respons
need
order
improv
protect
immun
prrsv
found
case
use
adjuv
inactiv
pseudorabi
viru
vaccin
like
prr
mlv
vaccin
stimul
weak
ifng
respons
clearli
studi
requir
clarifi
outcom
prrsv
infect
influenc
intens
ifng
respons
memori
cell
nevertheless
potenti
import
elicit
strong
ifng
respons
pathogen
might
limit
prevent
viru
replic
bautista
molitor
rowland
et
al
sinc
ifng
restrain
b
cell
differenti
even
polyclon
b
cell
activ
cowderi
fleme
reason
propos
strong
ifng
respons
could
mediat
protect
immun
thwart
polyclon
b
cell
activ
associ
prrsv
infect
result
immunopatholog
lemk
et
al
uncontrol
b
cell
activ
induc
prrsv
could
also
contribut
observ
weak
cellmedi
immun
respons
sinc
activ
b
cell
releas
burdin
et
al
cytokin
inhibit
ifng
product
porcin
cell
water
et
al
ifna
synthesi
human
pbmc
respons
viral
stimul
payvandi
et
al
accompani
manuscript
demonstr
pbmc
obtain
pig
week
immun
prr
mlv
spontan
secret
product
cytokin
inde
affect
administr
time
vaccin
ifna
express
plasmid
util
present
studi
repress
may
critic
sinc
unab
prrsv
infect
actual
stimul
synthesi
asai
et
al
known
inhibitor
th
cell
develop
diehl
rincon
promot
polyclon
immunoglobulin
product
follow
b
cell
activ
murin
arteriviru
lactat
dehydrogenaseelev
viru
markinegoriaynoff
et
al
strategi
design
shift
bia
initi
reaction
prrsv
strong
elicit
nonneutr
antibodi
product
toward
greater
th
immun
respons
worth
explor
sinc
could
conceiv
lead
develop
improv
vaccin
pathogen
need
develop
methodolog
made
palpabl
unusu
kinet
immun
respons
viru
evidenc
lack
mark
cmi
respons
upon
vaccin
subsequ
challeng
virul
viru
ifng
respons
prrsv
therefor
appear
determin
time
first
exposur
pathogen
minim
affect
reexposur
although
also
possibl
monitor
immun
respons
long
enough
postchalleng
detect
signific
increas
number
virusspecif
ifng
sc
unlik
sinc
accompani
manuscript
similar
minim
enhanc
observ
immun
respons
measur
week
booster
immun
addit
similar
limit
chang
ifng
respons
observ
upon
challeng
vaccin
pig
wildtyp
viru
foss
et
al
booster
immun
mlv
vaccin
meier
et
al
remark
tcell
prolif
respons
prrsv
also
increas
booster
immun
pig
previous
repeatedli
expos
mlv
vaccin
rather
appear
suppress
compar
elicit
vaccin
pig
bassaganyariera
et
al
mechan
respons
unusu
effect
current
unknown
might
relat
persist
viru
lymphoid
tissu
associ
site
infect
xiao
et
al
sustain
presenc
viru
could
advers
affect
subsequ
respons
due
inher
yet
unknown
properti
prrsv
summari
appar
prrsv
elicit
swine
polar
immun
respons
character
abund
nonneutr
antibodi
pauciti
ifng
sc
molecular
pathway
respons
gener
type
immun
unknown
time
base
result
present
like
involv
limit
induct
ifna
product
andor
inher
structur
element
viru
promot
respons
propos
strong
humor
immun
bia
host
respons
prrsv
mostli
respons
difficulti
develop
vaccin
deem
effect
field
although
use
porcin
cytokin
especi
ifna
adjuv
radic
affect
prrsv
inher
abil
promot
type
polar
immun
posit
impact
transit
lymphocyt
ifng
sc
notic
limit
upregul
cellular
ifng
respons
present
gene
express
describ
accompani
paper
royae
et
al
indic
substanti
stimul
innat
immun
modifi
host
respons
prrsv
perhap
potent
immunomodul
type
cpg
oligodeoxynucleotid
klinman
overcom
tendenc
prrsv
stimul
strong
nonneutr
antibodi
respons
simultan
promot
th
ifng
domin
respons
